Bona fide gift to Ted Karkus of 50000 shares of ProPhase Labs subject to Section 16
PRPH Stock | USD 0.42 0.03 6.67% |
Under 60% of ProPhase Labs' investor base is looking to short. The analysis of overall sentiment of trading ProPhase Labs stock suggests that many investors are alarmed at this time. ProPhase Labs' investing sentiment shows overall attitude of investors towards ProPhase Labs.
ProPhase |
Filed transaction by Prophase Labs Inc director. Exempt bona fide gift subject to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
ProPhase Labs' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the ProPhase Labs' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
ProPhase Labs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ProPhase Labs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ProPhase Labs Fundamental Analysis
We analyze ProPhase Labs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProPhase Labs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProPhase Labs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
ProPhase Labs is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
ProPhase Labs Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ProPhase Labs stock to make a market-neutral strategy. Peer analysis of ProPhase Labs could also be used in its relative valuation, which is a method of valuing ProPhase Labs by comparing valuation metrics with similar companies.
Peers
ProPhase Labs Related Equities
INBS | Intelligent Bio | 9.72 | ||||
STIM | Neuronetics | 6.56 | ||||
SERA | Sera Prognostics | 5.72 | ||||
PRPO | Precipio | 2.54 | ||||
SHC | Sotera Health | 1.97 | ||||
BNR | Burning Rock | 1.65 | ||||
XGN | Exagen | 0.74 | ||||
BDSX | Biodesix | 0.95 | ||||
STRR | Star Equity | 2.73 | ||||
DRIO | DarioHealth Corp | 3.03 | ||||
ENZ | Enzo Biochem | 4.76 |
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Fundamental Analysis View fundamental data based on most recent published financial statements |